California Public Employees Retirement System cut its stake in shares of Zogenix, Inc. (NASDAQ:ZGNX) by 1.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,875 shares of the company’s stock after selling 700 shares during the quarter. California Public Employees Retirement System owned 0.11% of Zogenix worth $2,524,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Tocqueville Asset Management L.P. raised its position in shares of Zogenix by 4.0% during the 4th quarter. Tocqueville Asset Management L.P. now owns 10,350 shares of the company’s stock valued at $377,000 after acquiring an additional 400 shares during the last quarter. Emory University boosted its position in Zogenix by 0.8% in the fourth quarter. Emory University now owns 57,822 shares of the company’s stock valued at $2,108,000 after buying an additional 448 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Zogenix by 20.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,956 shares of the company’s stock worth $108,000 after buying an additional 496 shares during the last quarter. Rhumbline Advisers raised its stake in Zogenix by 0.9% during the first quarter. Rhumbline Advisers now owns 57,361 shares of the company’s stock worth $3,155,000 after buying an additional 504 shares during the last quarter. Finally, Cohen Capital Management Inc. increased its stake in Zogenix by 1.5% in the fourth quarter. Cohen Capital Management Inc. now owns 36,048 shares of the company’s stock valued at $1,314,000 after purchasing an additional 540 shares in the last quarter.
Shares of ZGNX traded up $0.57 on Monday, reaching $48.35. The company’s stock had a trading volume of 771,500 shares, compared to its average volume of 652,841. The company has a quick ratio of 9.12, a current ratio of 9.12 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $2.03 billion, a PE ratio of -14.97 and a beta of 2.04. The company’s 50 day moving average price is $39.79. Zogenix, Inc. has a 12-month low of $33.43 and a 12-month high of $62.75.
A number of equities research analysts have recently issued reports on ZGNX shares. BidaskClub raised shares of Zogenix from a “sell” rating to a “hold” rating in a research note on Thursday, May 9th. Mizuho upped their price objective on shares of Zogenix from $58.00 to $65.00 and gave the stock a “positive” rating in a report on Friday. ValuEngine upgraded shares of Zogenix from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Svb Leerink decreased their price target on shares of Zogenix from $60.00 to $48.00 and set an “outperform” rating for the company in a research note on Tuesday, April 9th. Finally, Guggenheim lowered shares of Zogenix from a “buy” rating to a “neutral” rating and set a $40.00 price target for the company. in a research note on Tuesday, April 9th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $63.75.
Zogenix Company Profile
Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.
Featured Story: How is a buy-side analyst different from a sell-side analyst?
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.